Unexpected mechanism underlying mislocalization of thrombocytopenia-associated ETV6 point mutation

血小板减少症相关 ETV6 点突变错误定位的意外机制

• 批准号: 10605685
• 负责人: Michael R McConville
• 金额: $ 3.88万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-01-31 至 2026-01-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10605685
• 关键词: Affect; Amino Acids; Animal Model; Binding; Bioinformatics; Biological Models; Blood Platelets; Cell Maintenance; Cell Nucleus; Cell model; Cells; Chemicals; Childhood Precursor B Lymphoblastic Leukemia; Chronic Myelomonocytic Leukemia; ClinVar; Cytoplasm; DNA Binding; DNA Binding Domain; Data; Development; Disease; Dysmyelopoietic Syndromes; ETV6 gene; Exhibits; Family; Functional Imaging; Functional disorder; Genetic; Genetic Markers; Genetic Variation; Germ-Line Mutation; Goals; Hematologic Neoplasms; Hematopoietic; Heterozygote; Hour; In Vitro; Induced Mutation; Inherited; Knockout Mice; Malignant Neoplasms; Mammalian Cell; Maps; Mediating; Megakaryocytes; Missense Mutation; Mutate; Mutation; Nuclear; Nuclear Export; Penetrance; Peripheral; Platelet Count measurement; Point Mutation; Production; Proteins; RUNX1 gene; Recurrence; Risk; Signal Transduction; Somatic Mutation; Tertiary Protein Structure; Thrombocytopenia; Thrombopoiesis; Transcription Repressor; Transgenic Mice; Variant; Work; biophysical techniques; conditional knockout; exportin 1 protein; gene repression; genetic approach; human disease; inhibitor; leptomycin B; leukemia; meter; mouse model; mutant; mutation carrier; novel; novel marker; protein function; protein reconstitution; public database; stem cells; tool; transcription factor

PROJECT SUMMARY/ABSTRACT ETV6 is a transcriptional repressor involved inhematopoietic stem cell maintenance and terminal differentiation of megakaryocytes. ETV6 conditional knockout mice demonstrate a marked decrease in peripheral platelet counts and a compensatory increase in immature megakaryocytes. In concordance with these findings, in recent years, a number of germline mutations in ETV6 that result in mislocalization of the protein from the nucleus to the cytoplasm have been associated with inherited thrombocytopenia. Carriers of these mutations are also at an increased risk of hematologic malignancies as ~30% have gone on to develop myelodysplastic syndrome or leukemia. Most of these germline mutations are found in the DNA-binding domain (DBD) of ETV6. Functional studies of these DBD mutations demonstrate a loss of DNA-binding capacity in vitro and a loss of transcriptional repression in cells. However, one mutation, the Pro214Leu missense mutation identified in 5 families thus far, occurs in the long intrinsically disordered central domain of ETV6. It too demonstrates a loss of transcriptional repression in vitro, but the mechanism explaining this loss has not yet been established. Preliminary data I have gathered demonstrates that this Pro214Leu missense mutation creates a de novo nuclear export signal (NES) leading to exportin 1 (XPO1) mediated nuclear export. This constitutes the first described instance of a point mutation creating a de novo NES. We intend to develop cellular and animal model systems to probe the effects of this unexpected disease mechanism on thrombopoiesis. We are developing a homologous ETV6 P214L transgenic mouse line will validate its suitability as an animal model of ETV6-related thrombocytopenia. This will allow us to use genetic and chemical tools to study the effects of ETV6 P214L nuclear relocalization on megakaryocyte and platelet development. Lastly, a preliminary bioinformatics search utilizing ClinVar, a publicly available database of genetic variation, and an NES prediction server has yielded additional candidate mutations that may also create de novo NESs. We intend to show that missense mutation dependent nuclear export is a general mechanism of disease, and characterization of candidate NESs may yield novel biomarkers of disease.

项目总结/文摘